Abstract

The approval of teriflunomide (Aubagio—Genzyme) for the management of patients with relapsing forms of multiple sclerosis (MS) now offers this patient population a second oral treatment option. This approval follows the 2010 approval of Novartis's fingolimod (Gilenya), which has been plagued by a serious safety concern. In December 2011, FDA released a safety communication related to fingolimod after a patient died after beginning treatment. While the connections between the death and the drug were unclear, the fact that fingolimod can cause significant bradycardia and the recommendation that patients should be monitored for at least 6 hours after the first dose is seen as a problem by some.

Full Text

Published Version

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.